The takeaway
Mineralys Therapeutics, Inc. Common Stock shows a pronounced seasonal pattern over 3 years of data — strongest in February (+8.1%) and softest in April (−5.2%).
Right now
In July, the stock has fallen 67% of years, averaging −2.1%, roughly 4.3 pts behind the S&P 500.
The full picture
Mineralys Therapeutics, Inc. Common Stock's most dependable month has been February, higher in 2 of 3 years; April has been its least reliable, up just 33% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | — |
Month by month
The stock's clearest edge over the S&P 500 lands in March (+15.6 pts); it has trailed the market most in April (−6.9 pts).
“vs S&P” is Mineralys Therapeutics, Inc. Common Stock’s average for a month minus the S&P 500’s average for that same month — isolating Mineralys Therapeutics, Inc. Common Stock’s own seasonal edge from broad market drift.
Reality check
Over the last 3 years, February has closed higher 67% of the time versus 67% across the last 3 years — the pattern is holding.
Figures are the typical (median) February return and how often it rose — the last 3 years versus the last 3(the heatmap’s default window). This verdict stays anchored to that 3-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
No single month dominates — the stock carries a broad upward tilt, with 6 months rising more often than they fall and February (2 of 3 Februaries) nominally in front.
Its average (+8.1%) and median (+11.1%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even February ranges by 12.1% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: February has cleared the S&P 500 by +8.3 points above the index. It bucks the broad tape, besides: February lifts just 49% of stocks across the market.
A few other months pull their weight: May, July, and August have also closed higher more often than not. The weaker half of the year is plainer: April has been the soft spot — the weakest of 5 months that average a loss (−5.2%), and the edge isn't year-round — the stock has trailed the S&P 500 in April, November, and July. Its roughest month on record was a −26.4% September in 2023 — a reminder of how hard even a seasonal name can fall.
Treat it as a tendency rather than a rule — seasonality describes the past, not a promise. With a short 3-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (February), its worst (April), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2023 its best month (February, +8.1%) has run well ahead of its worst (April, −5.2%) — the heatmap above shows how steady that gap has been year to year.
February has been the strongest, averaging +8.1% and closing higher in 2 of 3 years since 2023.
It's the weakest, averaging −5.2% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade